ABC | Volume 111, Nº2, Agosto 2018

Diretrizes 3ª Diretriz Brasileira de Transplante Cardíaco Arq Bras Cardiol. 2018; 111(2):230-289 227. RochitteCE,AzevedoGS,ShiozakiAA,AzevedoCF,KalilFilhoR.Diltiazem as an alternative to beta-blocker in coronary artery computed tomography angiography. Arq Bras Cardiol. 2012;99(2):706-13. doi: http://dx.doi. org/10.1590/S0066-782X2012005000059. 228. Qiu S, Shi S, Ping H, Zhou S,Wang H, Yang B. Efficacy of ivabradine versus β -blockers forheartratereductionduringcomputedtomographycoronary angiography: ameta-analysis of randomized controlled trials. Cardiology. 2016;135(3):133-40. doi: 10.1159/000447236. 229. Javaheri A, Saha N, Lilly SM. How to approach the assessment of cardiac allograft vasculopathy in the modern era: review of invasive imaging modalities. Curr Heart Fail Rep. 2016;13(2):86-91. doi: 10.1007/s11897- 016-0283-y. 230. Erbel C, Mukhammadaminova N, Gleissner CA, OsmanNF, HofmannNP, Steuer C, et al. Myocardial perfusion reserve and strain-encoded CMR for evaluation of cardiac allograft microvasculopathy. JACC Cardiovasc Imaging. 2016;9(3):255-66. doi: 10.1016/j.jcmg.2015.10.012. 231. Chih S, Chong AY, Mielniczuk LM, Bhatt DL, Beanlands RS. Allograft vasculopathy: the Achilles' Heel of heart transplantation. J AmColl Cardiol. 2016;68(1):80-91. doi: 10.1016/j.jacc.2016.04.033. 232. Vallakati A, Reddy S, Dunlap ME, Taylor DO. Impact of statin use after heart transplantation: a meta-analysis. Circ Heart Fail. 2016;9(10). pii: e003265. doi: 10.1161/CIRCHEARTFAILURE.116.003265. 233. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, BoothroydDB, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. NEngl J Med. 1993;328(3):164-70. doi: 10.1056/NEJM199301213280303. 234. Erinc K, Yamani MH, Starling RC, Crowe T, Hobbs R, Bott-Silverman C, et al. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant. 2005;24(8):1033-8. doi: 10.1016/j.healun.2004.06.005. 235. Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, et al; A2310 IVUS Substudy Investigators. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail. 2013;1(5):389-99. doi: 10.1016/j.jchf.2013.07.002. 236. Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE et al; SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators. The effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo recipients: one-year results of a Scandinavian Randomized Trial. Am J Transplant. 2015;15(7):1967-75. doi: 10.1111/ajt.13214. 237. Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A, et al. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8- year results. J Heart Lung Transplant. 2015;34(5):634-42. doi: 10.1016/j. healun.2014.11.025. 238. Masetti M, Potena L, Nardozza M, Prestinenzi P, Taglieri N, Saia F, et al. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. Am J Transplant. 2013;13(5):1217-26. doi: 10.1111/ajt.12208. 239. Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, et al. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. Transplantation. 2011;92(2):235-43. doi: 10.1097/TP.0b013e31822057f1. 240. Matsuo Y, Cassar A, Yoshino S, Flammer AJ, Li J, Gulati R, et al. Attenuation of cardiac allograft vasculopathy by sirolimus: relationship to time interval after heart transplantation. J Heart Lung Transplant. 2013;32(8):784-91. doi: 10.1016/j.healun.2013.05.015. 241. de Lorgeril M, Dureau G, Boissonnat P, Ovize M, Monnez C, Monjaud I, et al. Increased platelet aggregation after heart transplantation: influence of aspirin. J Heart Lung Transplant. 1991;10(4):600-3. PMID: 1911805. 242. Prada-Delgado O, Estévez-Loureiro R, López-Sainz A, Gargallo- Fernández P, Paniagua-Martín MJ, Marzoa-Rivas R, et al. Percutaneous coronary interventions and bypass surgery in patients with cardiac allograft vasculopathy: a single-center experience. Transplant Proc. 2012;44(9):2657-9. doi: 10.1016/j.transproceed.2012.09.043. 243. Dasari TW, Hennebry TA, Hanna EB, Saucedo JF. Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature. Catheter Cardiovasc Interv. 2011;77(7):962-9. doi: 10.1002/ ccd.22975. 244. Goldraich LA, Stehlik J, Kucheryavaya AY, Edwards LB, Ross HJ. Retransplant and Medical Therapy for Cardiac Allograft Vasculopathy: International Society for Heart and Lung Transplantation Registry Analysis. Am J Transplant. 2016;16(1):301-9. doi: 10.1111/ajt.13418. 245. Zafar SY, Howell DN, Gockerman JP. Malignancy after solid organ transplantation: an overview. Oncologist. 2008;13(7):769-78. doi: 10.1634/theoncologist.2007-0251. 246. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-901. doi: 10.1001/jama.2011.1592. 247. Vajdic CM, van LeeuwenMT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125(8):1747-54. doi: 10.1002/ ijc.24439. 248. Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation. 2006;81(6):888-95. doi: 10.1097/01.tp.0000203554.54242.56. 249. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. NEngl J Med. 2005;352(13):1371-3. doi: 10.1056/ NEJMe058018. 250. Andrade JP, Marin-Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, et al; Sociedade Brasileira de Cardiologia. I Diretriz Latino Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica. [I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy]. Arq Bras Cardiol. 2011;97(2 Suppl 3):1-48. PMID: 21952638. 251. Seguro LF, Braga FG, Avila MS, Mangini S, Beselli B, Franco GP, et al. Profile of heart transplant recipients in a Brazilian center: comparisonwith international registry. J Heart Lung Transplant. 2014;33(4 Suppl):S264. doi: http://dx.doi.org/10.1016/j.healun.2014.01695. 252. Mangini S, Alves BR, Silvestre OM, Pires PV, Pires LJ, Curiati MN, et al. Heart transplantation: review. Einstein (Sao Paulo). 2015;13(2):310-8. doi: http://dx.doi.org/10.1590/S1679-45082015RW3154 253. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas’ heart disease. Int J Cardiol. 2005;102(2):239-47. doi: 10.1016/j.ijcard.2004.05.025. 254. Ayub-Ferreira SM, Mangini S, Issa VS, Cruz FD, Bacal F, Guimarães GV, et al. Mode of death on Chagas heart disease: comparison with other etiologies. a subanalysis of the REMADHE prospective trial. PLoS Negl Trop Dis. 2013;7(4):e2176. doi: 10.1371/journal.pntd.0002176. 255. Bestetti RB, Theodoropoulos TA. A systematic review of studies on heart transplantation for patients with end-stage Chagas’ heart disease. J Card Fail. 2009;15(3):249-55. doi: 10.1016/j.cardfail.2008.10.023. 256. BarrosMV, Ribeiro AL, Machado FS, RochaMO. Doppler tissue imaging to assesssystolic function inChagasdisease.ArqBrasCardiol.2003;80(1):36- 40. doi: http://dx.doi.org/10.1590/S0066-782X2003000100004. 257. Rochitte CE, Oliveira PF, Andrade JM, Ianni BM, Parga JR, Avila LF, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol. 2005;46(8):1553-8. doi: 10.1016/j.jacc.2005.06.067. 258. Regueiro A, Garcia-Alvarez A, Sitges M, Ortiz-Pérez JT, De Caralt MT, PinazoMJ, et al. Myocardial involvement in Chagas disease: Insights from cardiac magnetic resonance. Int J Cardiol. 2013;165(1):107-12. doi: 10.1016/j.ijcard.2011.07.089. 259. Rochitte CE, Nacif MS, deOliveira Junior AC, Siqueira-Batista R, Marchiori E,UellendahlM,etal.Cardiacmagneticresonance inChagas’disease.Artif Organs. 2007;31(4):259-67. doi: 10.1111/j.1525-1594.2007.00373.x. 260. Oliveira GC, Lopes LR, Andreollo NA, Braga Nda S, Coelho Neto Jde S. Surgical treatment of megaesophagus at UNICAMP Hospital of Clinics - associated factors with better and worse results. Rev Col Bras Cir. 2009;36(4):300-6. doi: http://dx.doi.org/10.1590/S0100- 69912009000400005. 288